Study highlights monocyte count in bleeding risk for thrombocytopenic dogs

Version 2 — Full analysis

A newly published retrospective study is pointing clinicians toward a more nuanced way to assess bleeding risk in dogs with severe thrombocytopenia. Reviewing 159 cases from 2012 to 2021, investigators found that clinically significant bleeding developed in 74 dogs, and that lower platelet count plus higher monocyte count predicted bleeding across the overall population. In dogs with immune thrombocytopenia, however, monocyte count remained associated with bleeding risk while platelet count did not. The paper was published online in 2026 in the Journal of Small Animal Practice. (eprints.gla.ac.uk)

That finding lands in a clinical area where prognostic clarity has been limited. Immune thrombocytopenia is one of the most common causes of severe thrombocytopenia in dogs, but it remains a diagnosis of exclusion, and bleeding severity has long been recognized as variable even among dogs with similarly low platelet counts. A 2024 prospective cohort study in JVIM noted that platelet counts at admission were poorly predictive of bleeding severity or treatment response in primary ITP, underscoring the need for better markers at presentation. Smaller retrospective work from primary care has also suggested that other hematology variables may add value: in one study, platelet count and plateletcrit helped distinguish ITP from non-ITP thrombocytopenia, while mean platelet volume was associated with bleeding and treatment response within the ITP group. (onlinelibrary.wiley.com)

The new study set out to answer two practical questions: which dogs with severe thrombocytopenia are most likely to bleed significantly, and do the predictors differ between immune thrombocytopenia and other causes. According to the abstract, dogs with clinically significant bleeding had lower platelet counts and plateletcrit, and higher leukocyte and monocyte counts. On multivariable analysis, platelet count and monocyte count were independent predictors in the overall cohort. In the immune thrombocytopenia subgroup, monocyte count, but not platelet count, was associated with bleeding risk, suggesting inflammatory or immune-system activity may be contributing to hemorrhagic risk beyond the degree of thrombocytopenia alone. That last point is an inference from the association, not a demonstrated mechanism. (eprints.gla.ac.uk)

The platelet-count finding is especially notable because it both aligns with and sharpens earlier guidance. The 2024 ACVIM consensus statement on diagnosis of ITP in dogs and cats says there is moderate evidence that, in dogs with primary ITP and platelet counts below 50,000/μL, admission platelet count should not be used alone to predict disease outcome or guide treatment, even though it may relate to hemorrhage at presentation. Earlier retrospective work also found that melena and high BUN, rather than platelet count itself, were associated with worse prognosis in canine immune-mediated thrombocytopenia. (ebvminpractice.org)

The newer paper also intersects with another unresolved question: whether platelet-related indices can add diagnostic or prognostic value beyond the raw platelet count. In a small primary-care retrospective study published in the Journal of Veterinary Diagnostic Investigation, platelet count and plateletcrit were significantly lower in dogs with ITP than in dogs with other causes of thrombocytopenia, with reported cutoffs of 8 × 10⁹/L and 0.0001 L/L showing high sensitivity and specificity in that cohort. The same study found that dogs with ITP who were bleeding had significantly lower mean platelet volume, and dogs that responded to prednisolone monotherapy had higher platelet counts and higher MPV. In that dataset, a platelet count of at least 3 × 10⁹/L or MPV of at least 15.8 fL performed extremely well as outcome predictors, although the cohort was small. LDH isoenzyme patterns also differed between ITP and non-ITP groups, but specificity was limited, making them more supplementary than standalone markers. (Journal of Veterinary Diagnostic Investigation)

That context makes the current study's negative result on platelet mass measures clinically useful. The authors found that platelet mass metrics did not outperform platelet count as predictors of bleeding in their larger referral-hospital population. So while earlier smaller work hints that MPV may still have niche prognostic value within ITP, especially around bleeding phenotype or steroid response, the broader message remains that no single platelet-derived metric has yet emerged as a consistently superior tool across settings.

There doesn't yet appear to be extensive outside commentary specifically on this paper, but the result fits with broader expert discussion in the field. Educational and consensus sources have emphasized that spontaneous bleeding risk generally rises as platelet counts fall below roughly 30,000 to 50,000/μL, yet hemorrhage remains unpredictable at the individual-patient level. Clinician-facing reviews have also stressed that platelet count alone is an incomplete guide, and that dogs with ITP may present with very different bleeding phenotypes despite similarly severe thrombocytopenia. (cliniciansbrief.com)

Why it matters: For veterinary professionals, the practical takeaway is that CBC interpretation in severe thrombocytopenia may deserve a wider lens. If monocyte count is validated as a reproducible marker of bleeding risk, it could help emergency and internal medicine teams triage dogs more accurately, decide who needs closer monitoring, and better anticipate transfusion or hospitalization needs. It may be particularly useful in immune thrombocytopenia, where a very low platelet count alone may overestimate risk in some dogs and underestimate it in others. At the same time, earlier primary-care data suggest MPV may be worth watching as a possible signal for bleeding risk or treatment responsiveness, even if it is not yet ready to drive decisions on its own. That matters not just medically, but operationally, because ITP workups and treatment can be intensive and costly for pet parents. (onlinelibrary.wiley.com)

The study also adds to the ongoing discussion about whether platelet mass metrics offer more clinical value than simple platelet count. Here, the authors concluded those measures were not more predictive, which may limit enthusiasm for adding complexity unless future studies show a clearer benefit in specific subgroups. That could be reassuring for general practices and emergency hospitals that need decision support from readily available CBC data rather than specialized assays. It also helps frame where more specialized markers, such as LDH isoenzyme activity profiles, may fit: potentially informative in research or as adjuncts, but not yet practical replacements for routine hematology. (eprints.gla.ac.uk)

What to watch: The key next question is whether prospective, multicenter studies can confirm monocyte count as a clinically useful bleeding-risk marker and determine how it performs alongside structured bleeding scores, such as DOGiBAT, and other admission variables in dogs with suspected primary or secondary ITP. It would also be useful to see direct head-to-head evaluation of monocyte count, MPV, plateletcrit, and other CBC-derived indices across referral and primary-care populations, since the current evidence suggests some markers may be more helpful for diagnosis, others for bleeding risk, and others for treatment response. (onlinelibrary.wiley.com)